Congestive Heart Failure: When itraconazole was administered intravenously to dogs and healthy human volunteers, negative inotropic effects were seen. If signs or symptoms of congestive heart failure occur during administration of SPORANOX® (itraconazole) Injection, continued SPORANOX® use should be reassessed. (See CLINICAL PHARMACOLOGY: Special Populations, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS: Drug Interactions and ADVERSE REACTIONS: Post-marketing Experience for more information.)
Drug Interactions: Coadministration of cisapride, pimozide, quinidine, dofetilide, or levacetylmethadol (levomethadyl) with SPORANOX® (itraconazole) Capsules, Injection or Oral Solution is contraindicated. SPORANOX®, a potent cytochrome P450 3A4 isoenzyme system (CYP3A4) inhibitor, may increase plasma concentrations of drugs metabolized by this pathway. Serious cardiovascular events, including QT prolongation, torsades de pointes, ventricular tachycardia, cardiac arrest, and/or sudden death have occurred in patients using cisapride, pimozide, levacetylmethadol (levomethadyl), or quinidine concomitantly with SPORANOX® and/or other CYP3A4 inhibitors. (See CONTRAINDICATIONS, WARNING, and PRECAUTIONS: Drug Interactions for more information.)
For intravenous infusion (NOT FOR IV BOLUS INJECTION)
SPORANOX® (itraconazole) Injection/Oral Solution is indicated for empiric therapy of febrile neutropenic patients with suspected fungal infections. (NOTE: In a comparative trial, the overall response rate for itraconazole-treated subjects was higher than for amphotericin B-treated subjects. However, compared to amphotericin B-treated subjects, a larger number of itraconazole-treated subjects discontinued treatment due to persistent fever and a change in antifungal medication due to fever. Whereas, a larger number of amphotericin B-treated subjects discontinued due to drug intolerance. (See CLINICAL STUDIES section.)
SPORANOX® (itraconazole) Injection is also indicated for the treatment of the following fungal infections in immuno-compromised and non-immunocompromised patients:
Blastomycosis, pulmonary and extrapulmonary;
Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis; and
Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy.
Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.
(See CLINICAL PHARMACOLOGY: Special Populations, WARNINGS, and ADVERSE REACTIONS: Post-marketing Experience for more information).
Published Studies Related to Sporanox Injection (Itraconazole Injection)
Studies on itraconazole delivery and pharmacokinetics in mallard ducks (Anas platyrhynchos). [2005.06]
Avian aspergillosis is commonly treated with itraconazole (ITZ). This paper describes two studies using mallard ducks (Anas platyrhynchos)... ITZ pharmacokinetic parameters for both suspensions in mallard ducks were similar and the bioassay successfully measured ITZ equivalents in plasma samples from ducks.
Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. [2003.05.06]
BACKGROUND: Allogeneic hematopoietic stem-cell transplant recipients often receive fluconazole or an amphotericin B preparation for antifungal prophylaxis. Because of concerns about fungal resistance with fluconazole and toxicity with amphotericin B, alternative prophylactic regimens have become necessary. OBJECTIVE: To compare the efficacy and safety of intravenous and oral itraconazole with the efficacy and safety of intravenous and oral fluconazole for long-term prophylaxis of fungal infections... CONCLUSION: Itraconazole is more effective than fluconazole for long-term prophylaxis of invasive fungal infections after allogeneic hematopoietic stem-cell transplantation. Except for gastrointestinal side effects, itraconazole is well tolerated.
Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection. [2001.12]
This randomized, open-label, comparative study assessed the pharmacokinetics and safety of intravenous and oral hydroxypropyl-beta-cyclodextrin (HP-beta-CD) solutions of itraconazole in patients with advanced human immunodeficiency virus (HIV) infection... In conclusion, itraconazole 200 mg given intravenously twice daily for 2 days, then once daily for 5 days, rapidly achieves amean steady-state trough concentration of itraconazole of over 250 ng/ml, which is associated with clinic outcome and is effectively maintained with itraconazole oral solution 200 mg twice daily in patients with advanced HIV infection.
Effect of clarithromycin and itraconazole on the pharmacokinetics of ropivacaine. [2001.04]
In a double-blind, randomised, three-way cross-over study, eight healthy volunteers ingested daily for 4 days either 250 mg clarithromycin twice daily, 200 mg itraconazole once daily, or placebo... The interaction of clarithromycin with ropivacaine seems to be dose (concentration)-dependent.
The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. [2000.11]
OBJECTIVE: To examine the possible interaction of itraconazole with orally and intravenously administered dexamethasone... CONCLUSIONS: Itraconazole markedly increases the systemic exposure to and effects of dexamethasone. A careful follow-up is recommended when itraconazole or other potent inhibitors of the cytochrome P450 3A4 are added to the drug regimen of patients receiving dexamethasone.
Clinical Trials Related to Sporanox Injection (Itraconazole Injection)
A Randomized Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous Non-Small Cell Lung Cancer [Recruiting]
To evaluate the 3-month event-free survival of the combination of the combination of
itraconazole and pemetrexed in patients with recurrent/refractory non-small cell lung
To determine the objective response rate of the combination of itraconazole and pemetrexed
in patients with recurrent/refractory non-small cell lung cancer.
Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation [Recruiting]
- The primary objective of this study is to evaluate the efficacy and safety profile of
itraconazole as in primary prophylaxis
- The second objective of this study is to find the difference between long-term versus
short-term sequential therapy of Itraconazole (intravenous followed by oral
itraconazole) as primary prophylaxis of invasive fungal infections (IFI) in patients
undergoing allogeneic stem cell transplantation (allo-SCT)
- also to explore the relationship between the incidence of IFI with plasma
concentrations of itraconazole and hydroxy-itraconazole
Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail. [Active, not recruiting]
Onychomycosis is a common condition accounting for approximately half of all nail disorders.
It is most commonly caused by dermatophytes. Itraconazole has been approved for the treatment
of onychomycosis in the United States with an approved dosage regimen for the treatment of
onychomycosis of the toenail of once daily (QD) treatment with 200mg of itraconazole (two
100mg capsules) for 12 weeks. Barrier Therapeutics has developed a 200mg tablet which could
be used in a more convenient one-tablet-per-day dosing regimen. This clinical trial will
compare the efficacy and safety of this new tablet formulation with itraconazole capsules and
A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy [Recruiting]
This research is being done to test an investigational drug, called itraconazole, in the
treatment of prostate cancer. Itraconazole is approved by the Food and Drug Administration
(FDA) for the treatment of various fungal infections such as fingernail/toenail infections
and other more serious fungal infections. The word "investigational" means that itraconazole
is not approved for use in people with cancer. However, the FDA is allowing the use of
itraconazole in this research study. Itraconazole has been shown to have activity against
cancer (including prostate cancer) in the laboratory, but has not been tested against cancer
The purpose of this study is to find out:
- If itraconazole is safe when given at two different doses
- How itraconazole affects prostate specific antigen (PSA): a blood test that measures
substances released by prostate cancer
- Whether itraconazole can delay further prostate cancer growth and spread
- How itraconazole affects other markers of prostate cancer
Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas [Recruiting]
BCCs are the most common human cancer in the US and affect over 1 million people. There is
no effective drug to prevent basal cell carcinomas of the skin. We hope to learn if an oral
antifungal drug, Itraconazole, might inhibit a marker of proliferation and a biomarker
(tumor signaling pathway) of BCC development. Itraconazole is an FDA-approved drug for the
treatment of fungal infections of the skin, and has been used for the past 25 years with
relatively few side effects. It has been shown in mice to reduce a BCC biomarker and to
reduce growth of BCCs. Thus, it could potentially reduce BCC growth in humans.
Page last updated: 2006-01-31